Related Experiment Videos
[Meningococcal vaccines: present status and perspectives].
Jean-Michel Alonso1, Muhamed-Kheir Taha
1Unité des Neisseria, Centre National de Référence des Méningocoques, Departement de Médecine Moléculaire, Institut Pasteur, Paris, France. jmalonso@pasteur.fr
Therapie
|September 1, 2005
Summary
Meningococcal vaccines protect against invasive diseases caused by Neisseria meningitidis. Current vaccines target specific serogroups, but development of a serogroup B vaccine is ongoing, addressing a critical public health need.
Area of Science:
- Bacteriology and Immunology
- Vaccine Development
- Public Health
Context:
- Neisseria meningitidis is a significant cause of bacterial meningitis and septicemia.
- Existing vaccines target specific serogroups (A, C, Y, W135) but not serogroup B.
- Serogroup B vaccines are under development using outer membrane proteins.
Purpose:
- To review the current landscape of meningococcal vaccines.
- To highlight the limitations of existing polysaccharide-based vaccines.
- To discuss the ongoing efforts in developing vaccines against serogroup B.
Summary:
- Meningococcal vaccines, primarily polysaccharide-based, induce protective antibodies against invasive meningococcal disease.
- Conjugate vaccines are available for serogroups A, C, Y, and W135.
- A significant gap exists for serogroup B, with outer membrane protein vaccines in evaluation.
- Polysaccharide vaccines' serogroup specificity raises concerns about potential strain selection.
- Vaccine use is recommended for identified clonal expansions matching vaccine serogroups.
Impact:
- Informing vaccination strategies for meningococcal disease prevention.
- Guiding research and development for broader meningococcal vaccine coverage.
- Addressing the challenge of serogroup B meningococcal disease globally.